Itziar Irurzun‐Arana

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Timothy A. Yap, Matthew Krebs, Sophie Postel‐Vinay et al. · Clinical Cancer Research · 2021 · 136 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer

Minsuk Kwon, Gahyun Kim, Ryul Kim et al. · Journal for ImmunoTherapy of Cancer · 2022 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer

Seung Tae Kim, Simon A. Smith, Peter G. Mortimer et al. · Clinical Cancer Research · 2021 · 79 citations · Full text

Medicine, Oncology, Pharmacology +15

Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.

Mafalda Oliveira, Erika Hamilton, Jason Incorvati et al. · Journal of Clinical Oncology · 2022 · 42 citations

Medicine, Oncology, Pharmacology +15

A systems pharmacology model for inflammatory bowel disease

Violeta Balbas‐Martinez, Leire Ruiz-Cerdá, Itziar Irurzun‐Arana et al. · PLoS ONE · 2018 · 37 citations · Full text

Life Sciences, Immunology, Pharmacology +17